PublicWire | Emerging Market Stock News
  •  Home
  • Technology
  • Medical
  • Energy
  • Cannabis
  • Finance
  • Retail
  • General
  • Podcast
  • Videos
  • Services
  •  Home
  • Technology
  • Medical
  • Energy
  • Cannabis
  • Finance
  • Retail
  • General
  • Podcast
  • Videos
  • Services
No Result
View All Result
PublicWire
No Result
View All Result

Home » Medical » Cannabis Watch: Aurora Cannabis leads sector after stock is named Top Pick at Cowen

Cannabis Watch: Aurora Cannabis leads sector after stock is named Top Pick at Cowen

Cannabis Watch: Aurora Cannabis leads sector after stock is named Top Pick at Cowen

by PublicWire
April 26, 2019
in Medical
Reading Time: 5 mins read
0

Cannabis shares were mostly higher Tuesday, with Aurora Cannabis Inc. a standout, after Cowen designated the stock its Top Pick in the sector, citing growth opportunities in the Canadian legal recreational market and burgeoning international medical market.

Aurora stock

ACB, -5.64%

ACB, -5.32%

 rose 9%, after Cowen assigned it an outperform rating and C$14 price target ($10.50), equal to 46% above its current trading level.

“The company’s large cultivation footprint, capable of producing over 575,000 kg, provides ACB with the necessary infrastructure to weather early storms in adult use while continuing to grow higher-value revenues in the medical market,” analysts led by Vivien Azer wrote in a note.

Cowen is expecting the Canadian recreational and medical markets to represent a total addressable market of about C$12 billion by 2025. It expects the international medical market to grow to $31 billion by 2024, up from a previous estimate of just $9 billion.

See also: Canada’s black market for cannabis remained strong in fourth quarter

Aurora’s presence in 23 international markets should boost its ability to capture global market share, said the note. Cowen is expecting Aurora to generate revenue of C$305 million in fiscal 2019, rising to C$742 million by fiscal 2020 and to C$1.34 billion by fiscal 2022.

Cronos Group Inc.

CRON, -6.38%

 shares reversed early losses to trade up 7.6%, after Cowen initiated coverage of that stock with a market perform rating and C$29 price target, that is just above its current price of C$28.56.

Don’t miss: How the unsteady rise of the pot industry has made dime bags a billion-dollar business

Also: How marijuana companies can profit without selling pot

“We like CRON’s story as an asset-light, global low-cost producer with operational support and significant invested capital from Altria Inc.,” Azer wrote in a note. “However, valuation prevents us from taking a more constructive position at this time.”

Also Tuesday, medical cannabis information website Leafly said a data team working with Whitney Economics estimates that legal cannabis has created more than 211,000 jobs across the U.S., about 64,000 of which were added in 2018.

The cannabis workforce rose 21% in 2018 and 44% in 2018, according to their research and is expected to climb at least another 20% in 2019. Because of the continued federal ban on cannabis, the U.S. government does not officially count cannabis jobs, nor are they included in official statistics or economic reports.

In Colorado, a House panel advanced a bill that aims to open the state’s $1.4 billion-a-year recreational and medical market to new sources of public and private capital, as MJBizdaily.com reported.

“The lack of investment opportunity is the single-biggest burden we have,” Shannon Fender, director of public affairs of Native Roots, one of Colorado’s largest marijuana operators, told the committee’s public hearing.

See also: Washington moves closer to delivering protections for banks that work with the pot industry

MedMen Enterprises Inc.

MMNFF, +4.41%

 was down 2.2%, after the company acknowledged that it had engaged a firm called Wining Media LLC to provide public relations and communications for the company, that included promoting its stock through ads on Google and Yahoo Finance, along with an article on a website called marijuanastox.com. The company’s former finance head alleged in a lawsuit that it had hired a consultant to prop up the stock, a claim the company initially dismissed as baseless.

For more, see: MedMen cuts fundraising round nearly in half, as CFO quits

But MedMen said late Monday that after receiving inquiries from OTC Markets Group, it looked into the matter and discovered Wining did use statements that “encourage investors to purchase the stock of the company.”

“The company has concluded, upon investigation, that, in this instance the article was not approved according to the company’s internal procedures,” it said in a statement.

MedMen “disclaims any potentially exaggerated or misleading statements contained in the materials,” and has instructed Wining to remove all promotional materials from the public domain and to cease all promotional efforts on its behalf. It acknowledged that it has hired five separate companies to provide investor relations, PR services and marketing including the promotion of its securities in the past year.

Elsewhere in the sector, Tilray Inc.

TLRY, -4.40%

 was up 0.4%, Hexo Corp.

HEXO, -6.19%

was down 0.8% and Aleafia health Inc.

ALEF, -0.44%

ALEF, -0.44%

was up 6%. OrganiGram Holdings Inc.

OGRMF, -2.41%

was up 2.8%, CannTrust Holdings Inc.

CTST, -3.31%

TRST, -3.01%

 was up 1.5%.

GW Pharmaceuticals PLC

GWPH, -4.07%

 was flat and Green Growth Brands Inc.

GGBXF, -2.02%

 was down 0.8%.

See: People in states where marijuana is legal are eating more cookies and ice cream

The Horizons Marijuana Life Sciences ETF

HMMJ, -3.42%

was up 3% and the ETFMG Alternative Harvest ETF

MJ, -4.19%

was up 1.9%.

The S&P 500

SPX, -1.90%

and the Dow Jones Industrial Average

DJIA, -1.77%

were flat.

For all of MarketWatch’s coverage of cannabis companies, click here.

Read More

Previous Post

Marijuana Retailer MedMen Is Near an All-Time Low — Is the Stock Ready to Rebound?

Next Post

INVO Bioscience Launches Embryology Center in the Bay Area to Support Dedicated INVOcell Clinic Being Developed by Dr. Aimee, the “Egg Whisperer”

PublicWire

At PublicWire, we know the vast majority of all investors conduct their due diligence and get their news online in a variety of ways including email, social media, financial websites, text messages, RSS feeds and audio/video podcasts. PublicWire’s financial communications program is uniquely positioned to reach these investors throughout the U.S. and Canada as well as on a global scale.

Related Posts

Medical

FDA advisory panel recommends Moderna, Johnson & Johnson vaccine booster shots

October 18, 2021
0
Medical

Walgreens invests $5.5B to accelerate new healthcare business segment

October 18, 2021
0
Medical

Mayo Clinic to study respiratory muscle training as long COVID treatment

October 18, 2021
0
Medical

Anthem, Providence tap Vim for value-based care platform deployment

October 25, 2021
0
Medical

Healthcare lost 17,500 jobs in September amid ongoing labor shortage

October 25, 2021
0
Medical

Cigna divests life, accident and supplemental benefits businesses for $5.75B

October 25, 2021
0
Next Post
INVO Bioscience Launches Embryology Center in the Bay Area to Support Dedicated INVOcell Clinic Being Developed by Dr. Aimee, the “Egg Whisperer”

INVO Bioscience Launches Embryology Center in the Bay Area to Support Dedicated INVOcell Clinic Being Developed by Dr. Aimee, the "Egg Whisperer"

Please login to join discussion

Subscribe To Our Newsletter

Loading
Ad
PublicWire | Emerging Market Stock News 24/7 | Investor Relations US Stock Market

© Copyright 2022 publicwire.com

Navigate Site

  • About
  • Contact Us
  • Disclaimer
  • Watch LIVE
  • Privacy Policy
  • Terms and Services
  • Contributors

Follow Us

No Result
View All Result
  • LIVE Investor News Channel
  • Cannabis
  • Energy
  • Finance
  • General
  • Medical
  • Podcasts
  • Retail
  • Technology
  • Videos

© Copyright 2022 publicwire.com

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.